GLPG News & Events

Galapagos (GLPG) announced the appointment of Tania Philipp as chief human resources officer, or CHRO, effective March 4. Philipp will also join the management committee. She succeeds Annelies Missotten, who will remain with the company through June 30, to ensure a transition. Most recently, she served as an executive human resources consultant at Vor Bio (VOR).

Galapagos announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its board of directors has decided to initiate the wind-down of the company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now concluded the works council consultation process regarding our intention to wind down the Company's cell therapy activities. We thank our dedicated colleagues for their commitment during this time of uncertainty as we now turn to executing the wind-down," said Henry Gosebruch, CEO of Galapagos. "As we move forward, we will seek to continue the evolution of Galapagos through transformative business development." The wind-down will impact approximately 365 employees across Europe, the U.S. and China, and will result in the closure of the sites in Leiden, Basel, Princeton, Pittsburgh and Shanghai.

Galapagos (GLPG) announced the topline results from two Phase 3-enabling studies evaluating the efficacy and safety of GLPG3667, a selective TYK2 inhibitor, in patients with dermatomyositis and active systemic lupus erythematosus. The GALARISSO DM study met its primary endpoint, showing that GLPG3667, administered once daily at 150 mg in addition to standard-of-care therapy, achieved a statistically significant clinical benefit in the Total Improvement Score at Week 24, compared to placebo. The pre-specified threshold of statistical significance was set at 10%. GLPG3667 also showed meaningful clinical improvements compared to placebo on several secondary endpoints of disease activity, including TIS20, TIS40, TIS60 and m-CDASI-A2. GLPG3667 demonstrated a favorable safety and tolerability profile throughout the 24-week treatment period. In the GALACELA SLE study, GLPG3667, administered once daily at 75 mg and 150 mg in addition to standard-of-care therapy, the primary endpoint analysis of dose-response on SLE responder index -4 at Week 32 did not meet statistical significance. However, GLPG3667 showed numerical improvements over placebo on several secondary endpoints, particularly on skin-related outcomes. The safety profile was consistent with previous studies with GLPG3667. The GALACELA study is currently ongoing, and the final Week 48 data, expected in the second quarter of 2026, will be essential to assess the totality of the evidence and determine potential next steps for the SLE program. The company aims to present data at an upcoming medical conference. Gilead (GILD) agreed to temporarily waive certain rights under the 10-year global option, license and collaboration agreement between Galapagos and Gilead, enabling Galapagos to pursue external partnership opportunities for GLPG3667.

Galapagos announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation at the American Society of Hematology annual meeting. As of September 2, 26 heavily pretreated MCL patients had undergone leukapheresis and 25 had received an infusion of GLPG5101. Of these, 24 patients received a fresh product, with 23 infused within seven days after apheresis. Among infused patients, the objective response rate was 100%, with a complete response rate of 96%. Duration of response and progression-free survival rates were both 83% at a median follow-up of nine months. Overall, 9 of 10 of minimal residual disease-evaluable patients were MRD-negative at CR and 7 of 9 MRD-negative patients remained in CR at the time of the data cut-off. GLPG5101 showed an encouraging safety profile. The most common grade greater than or equal to 3 treatment-emergent adverse events were hematologic. No grade greater than or equal to 3 CRS was observed, and only one case of Grade greater than or equal to 3 ICANS occurred. GLPG5101 demonstrated in vivo CAR T-cell expansion and long-term persistence with an enrichment of early memory phenotypes. As announced on October 21, and following an evaluation and sales process, Galapagos remains focused on the intention to wind down the cell therapy activities. This intention is subject to the conclusion of consultations with works councils in Belgium and the Netherlands, during which Galapagos will continue to operate the business and conduct ongoing clinical studies. Galapagos would still consider any viable proposal to acquire all, or part of the cell therapy business, should such a proposal emerge during the wind down process.